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Gene therapy is suggested to be one of the most specific and efficient modulations for gene deficient diseases and
extended to other diseases like cancer and inflammation, even though there are still challenges to be faced, such
as specific and selective delivery, minimal to no toxicity, efficient metabolism, simplicity, and measurable efficiency.
It is important to identify and validate drug-able disease-specific targets for molecular and cellular therapies, while it
is equally important to have disease biomarkers to trace and define the biological effects of molecular and cellular
therapies. The importance and significance of allostery in molecular and cellular therapies and “allosteric disease”,
“allosteric effect”, and “allosteric drug” should be more carefully examined and validated. Cell therapy has been
attracting an increasing amount of consideration in the development of new treatments for diseases. Molecular and
Cellular Therapies (MCT) is a new, open-access journal, devoted to molecular mechanisms, preclinical and clinical
research and development of gene-, peptide-, protein-, and cell-based therapies.
Keywords: Molecular therapy, Cellular therapy, Disease, JournalWelcome to the open-access journal titled Molecular
and Cellular Therapies (MCT), a new international jour-
nal devoted to molecular mechanisms, preclinical and
clinical research and development of gene-, peptide-,
protein-, and cell-based therapies, including target
identification and validation, safety, toxicity, efficacy,
efficiency, pharmacokinetics, metabolism, formulation,
delivery, pharmacovigilance, biomarkers, and new drug
applications. MCT will integrate interdisciplinary fields
such as genetics, cell biology, drug development, thera-
peutics, and new methods in biotechnology toward
translational medicine. MCT aims to establish a scientific
channel to translate the understanding of molecular and
cellular therapies to clinical and medical applications, to
improve the survival rate and quality of life for patients.
Alterations of gene frequencies were considered and
proposed to be responsible for the development of dis-
eases by Wright at the beginning of 2000s [1,2]. Gene
therapy is suggested to be one of the most specific and* Correspondence: xiangdong.wang@clintransmed.org
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reproduction in any medium, provided the orefficient modulations for gene deficient diseases and ex-
tended to other diseases like cancer and inflammation,
although there are still challenges to be faced, e.g. deliv-
ery, toxicity, metabolism, simplicity, and measurable effi-
ciency. The number of preclinical studies on molecular
therapies recently increased and covered many aspects.
For example, single-stranded antisense oligonucleotides
(ss-siRNAs) had the therapeutic potency of about 100
fold more than unmodified RNA and about 30 fold-
more than allele-selective inhibitors of mutant hunting-
tin expression in cells derived from patients [3,4]. Such
chemically modified ss-siRNAs could function under the
need of Argonaute protein and through the RNAi path-
way and provide allele-selective compounds for clinical
development. This study showed that intraventricular
infusion of ss-siRNA could selectively silence the mutant
humtingtin allele throughout the brain in a mouse
model. However, the metabolism, absorption, pharmaco-
logical dynamics and kinetics, protein binding, and elim-
ination of ss-siRNA remain unclear. It is also not clear
how ss-siRNA passes the brain, the tissue microenviron-
ment, and the circulation and how it is penetrating into
the cell. Furthermore, intracellular pharmacological pro-
files and associated metabolism of ss-siRNA may differtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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demonstrated that ss-siRNA could target and inhibit
mRNA both in vitro and in vivo by recruiting the RISC
endoribonuclease Ago2 to cleave the mRNA [5]. About
50 phosphate analogs were suggested to be critical for
the in vivo activity of ss-siRNA, rather than other forms
like small interfering RNA due to the variation of human
Ago2 activity, intrinsic potency, nuclease stability, and
pharmacokinetics. An additional challenge of RNA in-
hibitors as one of the most attractive molecular therapies
is how those inhibitors can identify and target the spe-
cific target cells within the tissue in order to maximize
the therapeutic efficiency of such inhibitors. Nucleotide
modifications have been considered to enhance meta-
bolic stability and protein binding of the ss-siRNA to
improve the rapid clearance of the oligonucleotides. On
the other hand, the high protein binding of inhibitors
will reduce the release and the biological efficacy of
drugs within the tissue. An additional challenge is the
delivery of oligonucleotides into the appropriate cells
[6]. While even potent molecules need delivery strategies
to overcome toxicity, specificity and metabolic degrad-
ation, there are numerous strategies currently being de-
vised to address some of these challenges in cancer [7],
inflammation [8], and viral infection [9].
It is also important to identify and validate drug-able
disease-specific targets for molecular and cellular ther-
apies, while it is equally important to have disease bio-
markers to trace and define the biological effects of
molecular and cellular therapies. Clinical bioinformatics
was suggested to play an important and critical role in
identification and validation of those disease-specific
biomarkers, including omics technology, metabolic and
signaling pathways, biomarker discovery and develop-
ment, computational biology, genomics, proteomics,
metaboliomics, pharmacomics, transcriptomics, high-
throughput image analysis, human molecular genetics,
human tissue bank, mathematical biology and medicine,
protein expression and profiling and systems biology
[5,10]. We should focus more on the combination of
clinical measurements and signs with human tissue-
generated bioinformatics, understand clinical symptoms
and signs of disease development and progress, and im-
provement of therapeutic strategies. In addition, atten-
tion should also be made to map relationships that
integrate discrete elements that collectively direct global
function within a particular -omic category, with clinical
examinations, pathology, biochemical analysis, imaging
and therapies. In order to develop better therapies, we
should integrate new biotechnologies with the under-
standing of gene and protein functions, cell and organ
dysfunction, and pathology, related to clinical signs,
symptoms, findings, measures, prognosis and thera-
peutic effects.The additional strategy of molecular and cellular ther-
apies is suggested to balance the functioning regulation
of genes, proteins, cells, and organs, rather than to sim-
ply “knock-in” or knock-out” a gene, develop an inhibi-
tor for a protein. Nussinov and Tsai recently emphasized
the importance and significance of allostery in molecular
and cellular therapies and defined “allosteric disease”,
“allosteric effect”, and “allosteric drug” [11]. Allostery is
to modulate the single protein and the binding of an ef-
fector molecule at one site on the protein surface, which
leads to changing the conformation of another site and
then regulate protein activity associated with conform-
ational and functional transitions in individual proteins.
The first reaction is considered as allosteric site, while
the secondary reaction can be the active or binding site.
Allosteric mechanisms were proposed to be involved in
the development of the disease and during the action of
allosteric modulators (drugs). It was believed that new
classes of drug therapies would come from allosteric
drugs, rather than modifications of existing drug com-
pounds, especially for many un-drug-able targets. The
combinatorial allosteric drug regime should be the new
strategy of molecular therapies for intractable, tenacious
drug-resistant mutations to reach less toxicity but more
efficacies. For example, a recent study investigated the
effects of inhibitors targeting mutant genes as a differen-
tiation therapy for cancer and found that the inhibitor
could potently and selectively inhibit the tumor-
associated mutant isocitrate dehydrogenases 2/R140Q in
an allosteric manner [12]. Such inhibitor could induce
differentiation of TF-1 erythroleukemia and primary hu-
man acute myelogenous leukemia cells, through the allo-
stery and slow-tight binding of the inhibitor with mutant
genes at the dimer interface. These mutations alter
residues in the enzyme active sites and confer a
gain-of-function in cancer cells, resulting in the accumu-
lation and secretion of the oncometabolite (R)-2-
hydroxyglutarate.
Cell therapy has attracted an increasing amount of
attention in the development of new straties for the
treatment for a variety of human diseases. There are a
number of influencing factors that can decide the fate of
stem cells. For example, the extracellular matrix (ECM)
is a key component of the stem cell niche that can regu-
late stem cell behaviour, renewal or differentiation.
Within the ECM there are different types of protein
interactions that can trigger various cell responses via
diverse sensing mechanisms and downstream signaling
pathways [12]. The interaction between stem cells and
ECM can be influenced by the intrinsic transcriptional
or epigenetic state of a cell and the individual micro-
environmental cues, including topography, ECM com-
position and stiffness, although the exact mechanism(s)
by which ECM regulates the differentiation and renewal
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cell transplantation, it is also possible to re-initiate the
‘reawakening’ pathways existed during embryogenesis
for the repair of the injured tissue/organ. Non-myocytes
were reprogrammed into cardiomyocytes with the expres-
sion of transcription factors (GATA4, HAND2, myocyte-
specific enhancer factor 2C and T-box 5) and microRNAs
(miR-1, miR-133, miR-208 and miR-499) that control
cardiomyocyte identity, as a complementary approach for
organ regeneration and repair [13]. Jiang et al. inserted a
large, inducible single gene, XIST (the X-inactivation gene)
into the DYRK1A locus on chromosome 21, in Down's
syndrome pluripotent stem cells, to correct gene imbal-
ance across an extra chromosome for Down's syndrome
[14]. The XIST non-coding RNA was used to coat
chromosome 21 and trigger stable heterochromatin modi-
fications, chromosome-wide transcriptional silencing and
DNA methylation to form a 'chromosome 21 Barr body',
as a model to study human chromosome inactivation
and creates a system to investigate genomic expression
changes and cellular pathologies of trisomy 21 [15], free
from genetic and epigenetic noise. It is one of the most
successful achievements in the development of chromo-
some therapy. X inactivation is the transcriptional silen-
cing of one X chromosome copy per female somatic cell,
while exhibits considerable variation among species. It is
evolutional to use X inactivation strategies in the develop-
ment of stem cell therapies for inherited diseases. How-
ever, it is also important to understand the long-term
arrangement from strict paternal stem cells inherited X in-
activation, diversity of X inactivation strategies during cell
differentiation, dominance, linkage, recombination, and
sex-differential selection.
Protein-based drug development has been experien-
cing a vast array of opportunities as well as several chal-
lenges to overcome, even though it is well accepted that
protein-based drugs have higher affinity and specificity
from protein-protein interactions and are more effective
to target and modulate the signaling pathways respon-
sible for the occurrence of diseases. Brentuximab vedotin
(SGN-35) is an anti-CD30 monoclonal antibody (cAC10)
conjugated by a protease-cleavable linker to a micro-
tuxbule-disrupting agent, monomethyl auristatin E.
Brentuximab vedotin, has been approved as an effective
treatment for relapsed CD30-expressing Classical Hodg-
kin and systemic anaplastic large cell lymphomas.
Brentuximab vedotin was found to decrease cell prolifer-
ation, induce cell cycle arrest, trigger apoptosis of pri-
mary effusion lymphoma cells, inhibit tumor growth,
and improve the survival of animals with primary
effusion lymphoma [16]. Brentuximab vedotin and
Trastuzumab emtansine have been recently approved for
commercial distribution in the United States by the
Food and Drug Administration, as next generations ofclinically promising new antibody drug conjugate.
However, the complexity of human disease highlights
the need for alternatives that expand the therapeutic
repertoire beyond this single class of proteins, indicating
new opportunities and challenges for protein-based drugs.
Next-generation therapeutics of protein-based drugs fo-
cuses more on the interaction between ligands and recep-
tors, and should be combined in order to increase the
efficacy and efficiency and reduce the toxicity and side-
effect. These are only some examples for the vast data that
is currently under pre-clinical and clinical testing.
There is an urgent and immediate need to create a
forum to stimulate discussion and exchange of scientific
findings and understandings of molecular and cellular
therapies with a clear goal of treating diseases and im-
proving the quality of patients. MCT is the journal fo-
cusing on the clinical application of gene-, peptide-,
protein-, and cell-based drugs and keeping track of the
wealth of new information related to the topic. We have
the confidence to believe that the MCT will play an im-
portant, critical, and recognized role in understanding
the molecular mechanisms of molecular and cellular
therapies and developing the individual medicine and
therapeutic strategy.
In conclusion, we as Editors of MCT, are delighted to
welcome you to this new and exciting journal and thank
the scientists who have agreed to publish in the journal.
In setting up the journal, we owe an enormous debt of
gratitude to all professors and scientists for their encour-
agement, support, comments, suggestions, and contribu-
tions. With great supports from our Section Editors,
Associate Editors and Editorial Board Members, we
deeply believe that MCT will be well-received both by
preclinical, clinical and pharmaceutical scientists inter-
ested in molecular and cellular therapies and contribute
to better outcome for understanding the diseases and
developing new therapies. Involvement and contribu-
tions from a large group of scientists who work on mo-
lecular and cellular therapies are crucial to the success
of the journal.
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